The global preimplantation genetic diagnosis market is witnessing substantial growth, fueled by increasing infertility rates, rising awareness of genetic disorders, and advancements in assisted reproductive technologies. According to a recent report published by Allied Market Research, the market was valued at $81.52 million in 2020 and is projected to reach $217.19 million by 2030, growing at a CAGR of 10.4% from 2021 to 2030.
Market Overview
Preimplantation genetic diagnosis is an advanced technique used alongside in vitro fertilization (IVF) to detect genetic abnormalities in embryos before implantation. This technology enables healthcare providers to identify hereditary conditions and chromosomal abnormalities, thereby improving the chances of a healthy pregnancy.
The growing preference for PGD over traditional post-conception diagnostic methods is a key factor driving market expansion. By ensuring the selection of genetically healthy embryos, PGD significantly reduces the risk of inherited diseases and enhances successful pregnancy outcomes.
Key Growth Drivers
The PGD market is primarily driven by:
- Rising infertility rates worldwide, attributed to lifestyle factors such as stress, smoking, alcohol consumption, and poor diet
- Increasing prevalence of genetic disorders like Down syndrome, cystic fibrosis, and thalassemia
- Growing adoption of assisted reproductive technologies (ART), particularly in developing economies
- Advancements in genetic testing technologies, improving accuracy and efficiency
Additionally, the ability of PGD to support the creation of “savior siblings” and prevent severe hereditary diseases is boosting its acceptance among patients and healthcare providers.
Market Segmentation Insights
The PGD market is segmented based on test type, including:
- Chromosomal abnormalities
- Aneuploidy
- X-linked diseases
- Single gene disorders
- Human leukocyte antigen (HLA) typing
- Gender selection
Among these, aneuploidy testing holds a dominant share due to its widespread application in detecting chromosomal imbalances in embryos.
Regional Analysis
Regionally, North America dominated the global PGD market in 2020, owing to advanced healthcare infrastructure, higher adoption of IVF procedures, and increased healthcare spending. However, the Asia-Pacific region is expected to witness significant growth during the forecast period due to rising awareness, improving medical facilities, and increasing fertility treatments.
Competitive Landscape
Key players operating in the global PGD market include:
- Illumina Inc.
- Agilent Technologies, Inc.
- PerkinElmer, Inc.
- Quest Diagnostics Inc.
- Natera Inc.
- Invitae Corporation
These companies are focusing on technological advancements, strategic collaborations, and expanding their product portfolios to strengthen their market position.
Impact of COVID-19
The COVID-19 pandemic initially disrupted the PGD market due to the temporary closure of fertility clinics and delays in elective procedures. However, the market began recovering by early 2022, supported by the reopening of healthcare services and increased healthcare investments globally.
Future Outlook
The preimplantation genetic diagnosis market is poised for robust growth, driven by continuous innovations in genetic testing, increasing IVF success rates, and growing demand for personalized reproductive healthcare. Emerging trends such as non-invasive PGD techniques and expanding applications in genetic disease prevention are expected to create lucrative opportunities for market players in the coming years.
0 Comments